Real-World Studies
Real-World Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Squamous Urothelial Carcinoma
Zarka et alCancer immunology, immunotherapy : CII

In a retrospective cohort study across Mayo Clinic sites, investigators evaluated outcomes of enfortumab vedotin plus pembrolizumab (EV/Pembro) in 49 adults with urothelial carcinoma with squamous divergent differentiation or pure squamous cell carcinoma (SCC). Among the cohort, 35 patients (71.4%) received EV/Pembro as first-line metastatic therapy. Best overall response was retrospectively adjudicated from routine-care CT, MRI, and PET reports rather than uniform prospective RECIST 1.1 assessment.
EV/Pembro demonstrated clinically meaningful activity, achieving a retrospectively adjudicated objective response rate of 67.3%. Best overall responses included complete response in 29 patients (59.2%), partial response in 4 (8.2%), stable disease in 4 (8.2%), and progressive disease in 12 (24.5%). Median duration of response was 23.7 months (95% CI 16.0–not reached [NR]). Median progression-free survival (PFS) was 23.8 months (95% CI 7.8–NR), and median overall survival (OS) was 24.5 months (95% CI 11.1–NR).
In multivariable analysis, greater metastatic burden was associated with shorter OS (HR per additional metastatic site, 2.37; 95% CI 1.55–3.62; p < 0.001). No statistically discernible survival differences were observed by extent of squamous divergent differentiation, though subgroup analyses were underpowered. Exploratory pretreatment Nectin-4 analyses were descriptive and limited to 12 patients; the authors concluded that histology- and Nectin-4-based findings require prospective validation.
Key Takeaways
- Enfortumab vedotin plus pembrolizumab yielded a retrospectively adjudicated objective response rate of 67.3% (complete response: 59.2%, partial response: 8.2%) with a median progression-free survival of 23.8 months (95% CI 7.8–NR) and median overall survival of 24.5 months (95% CI 11.1–NR).
- In multivariable analysis, greater metastatic burden was associated with shorter overall survival (HR per additional metastatic site, 2.37; 95% CI 1.55–3.62; p < 0.001), while no statistically discernible survival differences were observed by extent of squamous divergent differentiation.
Read the original sourceCancer immunology, immunotherapy : CII
